Company Overview and News

 
Thirumalai Chemicals Limited - Updates

2018-05-23 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Closing Bell: Sensex loses 188 pts; all sectoral indices end in the red except Nifty Bank

2018-05-04 moneycontrol
Market Closing: Benchmark indices closed sharply lower on Friday, with the Sensex falling 187.76 points to 34,915.38 and the Nifty declining 61.40 points to 10,618.30.

 
Market Live: Sensex falls 250 pts, Nifty breaks 10,600; rupee extends losses

2018-05-04 moneycontrol
Earnings: Ambuja Cements has reported standalone profit at Rs 271.8 crore for the quarter ended March 2018, a growth of 10.3 percent over Rs 246.5 crore reported in year-ago.

 
Thirumalai Chemicals Limited - Auditor's report

2018-05-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Market Live: Midcap corrects in line with frontliners, Sensex dips over 150 pts; Nifty Bank in the green

2018-05-04 moneycontrol
Market Update: The market was reeling under selling pressure, with the Sensex falling more than 150 points but the Nifty Bank traded in the green.

 
Market Live: Sensex falls over 150 pts; all sectoral indices in the red barring Realty

2018-05-04 moneycontrol
Market Update: The market extended losses in late morning deals, with the Sensex falling more than 150 points on global weakness amid US-China trade talks.

 
Thirumalai Chemicals gains 6% stock split recommendation, better Q4 PAT

2018-05-04 moneycontrol
Share price of Thirumalai Chemicals gained 6 percent intraday Friday as recommends sub division of equity share.

 
Market Live: Nifty extends losses, Sensex breaks 35,000; RIL, HDFC, Infosys, ITC drag

2018-05-04 moneycontrol
Services PMI: India’s service sector continued to improve at the start of the quarter, with business activity rising at a faster pace, supported by new order growth. Reflecting improvements in demand conditions, job creation accelerated to the sharpest since March 2011. Inflationary price pressures continued to ease further, with input and output charge inflation registering below their respective historical averages, Nikkei IHS Markit said.

 
Market Live: Sensex, Nifty open lower on global weakness; Bharti Airtel jumps

2018-05-04 moneycontrol
Rupee Update: The rupee edged 2 paise lower to 62.66 against the US dollar after opening one paisa higher after the greenback weakened overseas ahead of monthly US jobs report and China-US trade meet outcome.

 
Thirumalai Chemicals Limited - Trading Window

2018-04-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Thirumalai Chemicals Limited - Updates

2018-04-10 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Thirumalai Chemicals Limited - Disc. under Reg.30 of SEBI (SAST) Reg.2011

2018-04-03 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

 
Broker's call: Thirumalai Chemicals

2018-02-06 thehindubusinessline
Recently, the stock price of Thirumalai Chemicals corrected by about 30 per cent from 52-week high of ₹2,440 despite reporting good set of numbers in the recent quarters.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...